Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab + Sequential Hypofractionated Chemoradiotherapy in Unfit/Elderly Stage III NSCLC
NCT06656598Phase 2Recruiting
- Sponsor
- IFCT
- Start
- Nov 2025
- Primary completion
- Sep 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by IFCT. Started Nov 2025; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06656598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656598.